Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada; Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada; Molecular Biology Programs, Université de Montréal, Montreal, QC, Canada.
Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada.
Cancer Cell. 2024 Jul 8;42(7):1147-1151. doi: 10.1016/j.ccell.2024.05.023. Epub 2024 Jun 20.
Clinical practice and clinical research heavily rely on primary tumors, circulating tumor DNA, and/or overt metastases as sources of material for predicting or investigating breast cancer metastatic relapses. However, these approaches do not consider emerging fundamentals in the biology of metastatic dormancy and relapse. Conversely, the field of metastatic dormancy often discounts key clinical factors influencing relapse dynamics (e.g., patient's age and overall health condition). Here, we delineate these disparities into four gaps and propose a framework to bridge them.
临床实践和临床研究主要依赖原发性肿瘤、循环肿瘤 DNA 和/或明显转移作为预测或研究乳腺癌转移复发的材料来源。然而，这些方法并未考虑转移休眠和复发生物学中的新兴基础。相反，转移休眠领域通常忽略了影响复发动态的关键临床因素（例如，患者的年龄和整体健康状况）。在这里，我们将这些差异划分为四个差距，并提出了一个框架来弥合这些差距。
